Anidulafungin
Echinocandin Antifungal — ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: ecalta, eraxis, LY 303366, LY-303366
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Anidulafungin is an ofp drug in the Echinocandin Antifungal class catalogued in DrugCentral. It was first approved by the FDA in 2006. DrugCentral lists 1 molecular target, including GSC1. Recorded indications include Candida Peritonitis, Candidemia, Candidiasis of the esophagus and Disseminated candidiasis.
- Approval status: ofp (first approved 2006 by the FDA).
- Drug class: Echinocandin Antifungal.
- Molecular targets: GSC1 (1 listed in DrugCentral).
- Indications: Candida Peritonitis, Candidemia, Candidiasis of the esophagus, Disseminated candidiasis and Intra-Abdominal Candida Abscess.
- ATC code: J02AX06 (Other antimycotics for systemic use).
- Molecular formula: C58H73N7O17; molecular weight 1140.25 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (5)
- Candida Peritonitis
- Candidemia
- Candidiasis of the esophagus
- Disseminated candidiasis
- Intra-Abdominal Candida Abscess
Off-label uses (1)
- Oropharyngeal Candidiasis
Contraindications (2)
- Disease of liver
- Liver function tests abnormal
Mechanism & targets
| Established pharmacologic class | Echinocandin Antifungal |
|---|
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Beta-1,3-glucan synthase catalytic subunit 1 | GSC1 | inhibitor | IC50 7.75 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2007-09-20 | EMA | — | — | |
| 2006-02-17 | FDA | — | VICURON |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J02AX06 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › Other antimycotics for systemic use |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Multiple organ dysfunction syndrome | 330.5 |
| Septic shock | 212.5 |
| Drug ineffective | 172.7 |
| Candida infection | 161.7 |
| Sepsis | 133.0 |
| Enterococcal infection | 116.5 |
| Protothecosis | 114.6 |
| Pathogen resistance | 108.1 |
| Systemic candida | 106.8 |
| Drug resistance | 96.1 |
| Haemodynamic instability | 94.5 |
| Fungaemia | 94.1 |
Chemical structure
| Molecular formula | C58H73N7O17 |
|---|---|
| Molecular weight | 1140.25 g/mol |
| CAS number | 166663-25-8 |
| InChIKey | JHVAMHSQVVQIOT-FUVWCVBOSA-N |
| PubChem CID | 166548 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Anidulafungin used for?
DrugCentral lists the following indications for Anidulafungin: Candida Peritonitis, Candidemia, Candidiasis of the esophagus, Disseminated candidiasis and Intra-Abdominal Candida Abscess.
How does Anidulafungin work?
Its molecular targets in DrugCentral include GSC1 (inhibitor).
When was Anidulafungin first approved?
Anidulafungin was first approved by the FDA in 2006.
What drug class does Anidulafungin belong to?
Anidulafungin is in the Echinocandin Antifungal class.
What is the chemical formula of Anidulafungin?
Anidulafungin has the molecular formula C58H73N7O17 and a molecular weight of 1140.25 g/mol.
Browse: all drugs starting with A · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4357 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL264241 — compound record and bioactivity
- PubChem CID 166548 — chemical identifiers
- DrugBank DB00362 — drug record
- FDA UNII 9HLM53094I — substance identity
- DailyMed: FDA labels for Anidulafungin — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.